MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration
Giovanni Marconi(University of Bologna), Giovanni Martinelli(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Emanuela Ottaviani(University of Bologna), Mariachiara Abbenante(University of Bologna), Sarah Parisi(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Elena Tenti(University of Bologna), Antonella Padella(University of Bologna), Carmen Baldazzi(University of Bologna), Luca Bertamini(University of Verona), Nanni Jacopo(University of Bologna), Eugenio Fonzi(University of Bologna), Martina Pazzaglia(University of Bologna), Valentina Robustelli(University of Bologna)
Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)
December 7, 2017
Cited by 0
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486